118 related articles for article (PubMed ID: 9110406)
1. Nf1 gene targeting: toward models and mechanisms.
Cichowski K; Shih TS; Jacks T
Semin Cancer Biol; 1996 Oct; 7(5):291-8. PubMed ID: 9110406
[TBL] [Abstract][Full Text] [Related]
2. A mild mutator phenotype arises in a mouse model for malignancies associated with neurofibromatosis type 1.
Garza R; Hudson RA; McMahan CA; Walter CA; Vogel KS
Mutat Res; 2007 Feb; 615(1-2):98-110. PubMed ID: 17208258
[TBL] [Abstract][Full Text] [Related]
3. A mouse embryonic stem cell model of Schwann cell differentiation for studies of the role of neurofibromatosis type 1 in Schwann cell development and tumor formation.
Roth TM; Ramamurthy P; Ebisu F; Lisak RP; Bealmear BM; Barald KF
Glia; 2007 Aug; 55(11):1123-33. PubMed ID: 17597122
[TBL] [Abstract][Full Text] [Related]
4. Optic nerve glioma in mice requires astrocyte Nf1 gene inactivation and Nf1 brain heterozygosity.
Bajenaru ML; Hernandez MR; Perry A; Zhu Y; Parada LF; Garbow JR; Gutmann DH
Cancer Res; 2003 Dec; 63(24):8573-7. PubMed ID: 14695164
[TBL] [Abstract][Full Text] [Related]
5. Chromosome 17 loss-of-heterozygosity studies in benign and malignant tumors in neurofibromatosis type 1.
Rasmussen SA; Overman J; Thomson SA; Colman SD; Abernathy CR; Trimpert RE; Moose R; Virdi G; Roux K; Bauer M; Rojiani AM; Maria BL; Muir D; Wallace MR
Genes Chromosomes Cancer; 2000 Aug; 28(4):425-31. PubMed ID: 10862051
[TBL] [Abstract][Full Text] [Related]
6. Tumour predisposition in mice heterozygous for a targeted mutation in Nf1.
Jacks T; Shih TS; Schmitt EM; Bronson RT; Bernards A; Weinberg RA
Nat Genet; 1994 Jul; 7(3):353-61. PubMed ID: 7920653
[TBL] [Abstract][Full Text] [Related]
7. Constitutional NF1 mutations in neurofibromatosis 1 patients with malignant peripheral nerve sheath tumors.
Kluwe L; Friedrich RE; Peiper M; Friedman J; Mautner VF
Hum Mutat; 2003 Nov; 22(5):420. PubMed ID: 14517963
[TBL] [Abstract][Full Text] [Related]
8. Neurofibromatosis type 1 is a disorder of dysplasia: the importance of distinguishing features, consequences, and complications.
Riccardi VM
Birth Defects Res A Clin Mol Teratol; 2010 Jan; 88(1):9-14. PubMed ID: 19691086
[TBL] [Abstract][Full Text] [Related]
9. Somatic deletion of the neurofibromatosis type 1 gene in a neurofibrosarcoma supports a tumour suppressor gene hypothesis.
Legius E; Marchuk DA; Collins FS; Glover TW
Nat Genet; 1993 Feb; 3(2):122-6. PubMed ID: 8499945
[TBL] [Abstract][Full Text] [Related]
10. The Ras inhibitor farnesylthiosalicylic acid as a potential therapy for neurofibromatosis type 1.
Barkan B; Starinsky S; Friedman E; Stein R; Kloog Y
Clin Cancer Res; 2006 Sep; 12(18):5533-42. PubMed ID: 17000690
[TBL] [Abstract][Full Text] [Related]
11. Tumorigenic properties of neurofibromin-deficient Schwann cells in culture and as syngrafts in Nf1 knockout mice.
Wu M; Wallace MR; Muir D
J Neurosci Res; 2005 Nov; 82(3):357-67. PubMed ID: 16180234
[TBL] [Abstract][Full Text] [Related]
12. NF1 mutations in neurofibromatosis 1 patients with plexiform neurofibromas.
Kluwe L; Friedrich RE; Korf B; Fahsold R; Mautner VF
Hum Mutat; 2002 Mar; 19(3):309. PubMed ID: 11857752
[TBL] [Abstract][Full Text] [Related]
13. Absence of c-kit gene mutations in gastrointestinal stromal tumours from neurofibromatosis type 1 patients.
Kinoshita K; Hirota S; Isozaki K; Ohashi A; Nishida T; Kitamura Y; Shinomura Y; Matsuzawa Y
J Pathol; 2004 Jan; 202(1):80-5. PubMed ID: 14694524
[TBL] [Abstract][Full Text] [Related]
14. Molecular targets for emerging anti-tumor therapies for neurofibromatosis type 1.
Dilworth JT; Kraniak JM; Wojtkowiak JW; Gibbs RA; Borch RF; Tainsky MA; Reiners JJ; Mattingly RR
Biochem Pharmacol; 2006 Nov; 72(11):1485-92. PubMed ID: 16797490
[TBL] [Abstract][Full Text] [Related]
15. Modeling neurofibromatosis type 1 tumors in the mouse for therapeutic intervention.
Parada LF; Kwon CH; Zhu Y
Cold Spring Harb Symp Quant Biol; 2005; 70():173-6. PubMed ID: 16869751
[TBL] [Abstract][Full Text] [Related]
16. Malignant peripheral nerve sheath tumors (MPNST) in neurofibromatosis type 1 (NF1): diagnostic findings on magnetic resonance images and mutation analysis of the NF1 gene.
Friedrich RE; Kluwe L; Fünsterer C; Mautner VF
Anticancer Res; 2005; 25(3A):1699-702. PubMed ID: 16033085
[TBL] [Abstract][Full Text] [Related]
17. The angiogenic factor midkine is aberrantly expressed in NF1-deficient Schwann cells and is a mitogen for neurofibroma-derived cells.
Mashour GA; Ratner N; Khan GA; Wang HL; Martuza RL; Kurtz A
Oncogene; 2001 Jan; 20(1):97-105. PubMed ID: 11244508
[TBL] [Abstract][Full Text] [Related]
18. NF1 tumor suppressor in epidermal wound healing with special focus on wound healing in patients with type 1 neurofibromatosis.
Koivunen J; Karvonen SL; Ylä-Outinen H; Aaltonen V; Oikarinen A; Peltonen J
Arch Dermatol Res; 2005 Jun; 296(12):547-54. PubMed ID: 15856266
[TBL] [Abstract][Full Text] [Related]
19. The heterogeneous nature of germline mutations in NF1 patients with malignant peripheral serve sheath tumours (MPNSTs).
Upadhyaya M; Spurlock G; Majounie E; Griffiths S; Forrester N; Baser M; Huson SM; Gareth Evans D; Ferner R
Hum Mutat; 2006 Jul; 27(7):716. PubMed ID: 16786508
[TBL] [Abstract][Full Text] [Related]
20. Stimulus-evoked release of neuropeptides is enhanced in sensory neurons from mice with a heterozygous mutation of the Nf1 gene.
Hingtgen CM; Roy SL; Clapp DW
Neuroscience; 2006; 137(2):637-45. PubMed ID: 16298082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
